biologic

Vowst

fecal microbiota spores, live-brpk

Loss of exclusivityApril 2035FDA regulatory exclusivity expiry

CompanyAimmune Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand name	Vowst
Active ingredient	fecal microbiota spores, live-brpk
Strength	1X10 LOG 6 AND 3X10 LOG 7CFU/TAB
Dosage form	Capsule
Route	Oral
Modality	Biologic
FDA approval	April 2023
Marketing status	Rx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.